Medical/Pharmaceuticals
Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting
SHANGHAI, May 23, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including phase Ib/II clini...
2025-05-23 22:00
4303
41st WHO Sasakawa Health Prize Awarded to Denmark's Dr. Merete Nordentoft For Work on Suicide Prevention in Young People
TOKYO, May 23, 2025 /PRNewswire/ -- The 41st WHO Sasakawa Health Prize was
presented to Danish psychiatrist Dr.Merete Nordentoft in recognition of her
work on suicide prevention in young people, during a ceremony at the 78th World
Health Assembly inGeneva on May 23.
2025-05-23 21:00
4333
UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson's disease, in its Phase 1 study
SHANGHAI, May 23, 2025 /PRNewswire/ -- Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first administration of its proprietary Parkinson's disease cell drug UX-DA001 inChina in March 2025. The Phase I c...
2025-05-23 19:18
4836
Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting
* Preliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented. * These data highlight elacestrant's potential ro...
2025-05-23 18:07
3887
Six Abstracts of Kelun-Biotech's Clinical Studies Published at the 2025 ASCO Annual Meeting
CHENGDU, China, May 23, 2025 /PRNewswire/ -- The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, the "Company") will present results from six cl...
2025-05-23 17:24
4820
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure1-3 NICE's recommendation is based on clinically meaningful results from the phase-III PROTECT trial4 ST. GALLEN, Switzerland, May 23, 2025 /PRNewswi...
2025-05-23 16:16
4384
ADVANCING ENDOSCOPIC EXCELLENCE
Pantai Hospital Kuala Lumpur Reaches 50 POEM Cases, Leading the Way in Minimally Invasive, Incisionless Treatment KUALA LUMPUR, Malaysia, May 23, 2025 /PRNewswire/ -- Pantai Hospital Kuala Lumpur (PHKL) proudly celebrates a major milestone in its endoscopic journey, having successfully performe...
2025-05-23 14:28
2074
Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025
* ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant melanoma patients in the ongoing STAMINA-01 t...
2025-05-23 12:31
4652
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting
CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), today announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC...
2025-05-23 12:21
3305
Everest Medicines Announces NEFECON® Inclusion in China's Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)
SHANGHAI, May 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics,announced that NEFECON® has been included in the "Clin...
2025-05-23 11:39
2855
FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 22, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, to...
2025-05-23 10:44
2278
MindHYVE.ai™ and Islamabad Diagnostic Centre Forge Strategic Alliance to Launch AGI-Powered Diagnostic Intelligence Across Pakistan
ISLAMABAD, May 23, 2025 /PRNewswire/ -- In a groundbreaking move to elevate clinical diagnostics nationwide, MindHYVE.ai™, a U.S.-based pioneer in orchestrated agentic AI and swarm-intelligent systems, has signed a formal Memorandum of Understanding (MoU) with Islamabad Diagnostic Centre (IDC). T...
2025-05-23 09:18
2345
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-38, an Novel Epigenetic Immune Activator, at the 2025 ASCO Annual Meeting
TAIPEI, May 23, 2025 /PRNewswire/ -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-38, an novel epigenetic immune activator for cancer immunotherapy. GNTbm-38 was presented as posters at the 2025 American Association of Clinical Oncology (ASCO) Annual Meeting, which ...
2025-05-23 08:00
2471
Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, May 22, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI...
2025-05-23 08:00
3404
CARsgen's Satri-cel Abstract Available on ASCO Website
SHANGHAI, May 22, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that an abstract of the research results of the confirmatory Phase II clinical trial of satricabtagene autoleucel ("satri-...
2025-05-23 08:00
2207
Cellenkos Inc. and King Faisal Specialist Hospital & Research Centre, Sign Strategic MOU to Advance T Regulatory Cell Therapies for Unmet Diseases
* KFSHRC to lead Clinical Trials Targeting Aplastic Anemia and Graft vs. Host Disease * Cellenkos to Support Local Cell and Gene Therapy Manufacturing at KFSHRC RIYADH, Saudi Arabia and HOUSTON, May 22, 2025 /PRNewswire/ -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Cellen...
2025-05-22 23:47
2383
Pictor Establishes U.S. Headquarters and Scales Operations, Revolutionizing Proteomics Testing Amid Regulatory Shift
CARLSBAD, Calif., May 22, 2025 /PRNewswire/ -- Pictor, a global leader in multiplex proteomics solutions, is excited to announce the establishment of its U.S. headquarters in Carlsbad, California, marking a significant milestone in its strategic growth and commitment to advancing cutting-edge sol...
2025-05-22 21:42
2407
Porton Advanced Announces Collaboration with TongEYE to Accelerate Development of iPSC-RPEC transplantation therapy
SUZHOU, China, May 22, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with TongEye Medical Technology (TongEYE), an innovator focusing on...
2025-05-22 21:00
2154
EdgeCap-backed Comac Medical Group Expands with Acquisition of ILIFE Consulting, a French Early-phase Specialty CRO
Strategic acquisition marks significant step to establish pan-European footprint and deepens expertise in oncology and early-phase biotech clinical trials. LONDON, May 22, 2025 /PRNewswire/ -- Comac Medical Group ("Group"), based in the UK and backed by EdgeCap Partners, announced today the ac...
2025-05-22 20:20
2305
AXA Study: Over 60% of Hong Kong workers encounter elevated stress levels exceeding global average
Younger generation confronts critical mind health challenges, necessitating enhanced workplace support HONG KONG, May 22, 2025 /PRNewswire/ -- Work-related factors exert a greater influence on the mind health of Hong Kong's workforce compared to the global average, according to the latest finding...
2025-05-22 16:55
3564
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 312 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 304 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 302 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40
Most Read
GIGABYTE Strengthens NVIDIA® Partnership to Drive Innovation in AI-Powered Gaming and Creative Solutions
2026-01-17 00:00
7212
GAC Energy Releases 2025 EV Charging Ecosystem Report: Over 23,000 Self-Operated Charging Piles Across China
2026-01-17 10:59
5788
